FDA Approval Summary: Nivolumab for the treatment of relapsed or progressive classical Hodgkin lymphoma, Oncologist, vol.22, pp.585-591, 2017. ,
Pembrolizumab in classical Hodgkin's lymphoma, Eur J Haematol, vol.97, pp.219-227, 2016. ,
Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial, J Clin Oncol, vol.36, p.1428, 2018. ,
Superiority of allogenic stem cell transplantation after anti-pd1 therapy over anti-pd1 monotherapy alone in relapse/refractory Hodgkin lymphoma: real world evidence from the french early access program, Blood, vol.132, p.1638, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02076926
Nivolumab for relapsed/refractory diffuse large b-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study, J Clin Oncol, vol.37, pp.481-489, 2019. ,
PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation, Blood, vol.134, pp.22-29, 2019. ,
Long term benefit of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation, Eur J Cancer, 2019. ,
Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma, Blood, vol.131, pp.2856-2859, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01812478
Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma, Cochrane Database Syst Rev, vol.1, p.10533, 2015. ,
Adapted treatment guided by interim pet-ct scan in advanced Hodgkin's lymphoma, N Engl J Med, vol.374, pp.2419-2429, 2016. ,
PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study, Lancet Oncol, vol.20, pp.202-215, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-01996114
PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD, Blood, vol.130, pp.221-228, 2017. ,
Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma, J Clin Oncol, vol.35, pp.2125-2132, 2017. ,
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial, Lancet Oncol, vol.17, pp.1283-1294, 2016. ,
Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure, J Clin Oncol, vol.34, pp.3733-3739, 2016. ,
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma, N Engl J Med, vol.372, pp.311-319, 2015. ,
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0, Eur J Nucl Med Mol Imaging, vol.42, pp.328-354, 2015. ,
Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy, Blood, vol.128, pp.2489-2496, 2016. ,
, Kaplan-Meier estimate of mPFS according to ePET1 response Kaplan-Meier estimate of mPFS from anti PD-1 mAb initiation based on ePET/CT 1 response classification, stratifying patients in three mPFS risk groups: high (PMD), low (CMR) and intermediate